/

PLRX

Pliant Therapeutics, Inc.Closed

0.9680−0.02 −1.83%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.9900 +2.27%

Open

0.9826

Prev close

0.9860

Day range

0.96100.9976

52-week range

0.96101.95

Volume

284.64K0.68×

Mkt cap

59.94M

P/E ttm

—

Fwd P/E

-0.75

EPS ttm

-1.50

Div yield

0.00%

Earnings

Nov 12, 2026

From 52w high

−50.36%

Price Chart

Yahoo Finance · delayed

PLRXOct 13, 2026O 0.9830H 0.9980L 0.9610C 0.9680−0.0180 (−1.83%)Vol 284.60K

SMA 501.0941
SMA 2001.1870

1Y change −34.15% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PLRX Pliant Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.02%
1 month: −17.26%
3 months: −11.19%
6 months: −25.54%
Year to date: −20.66%
1 year: −35.03%

Valuation & ownership

Market cap: 59.94M
Enterprise value: −69.42M
P/E (ttm): —
Forward P/E: -0.75
PEG ratio: —
Price / book: 0.41
Price / sales (ttm): —
EV / EBITDA: 0.77
EPS (ttm): -1.50
EPS (forward): -1.28
Beta (5y monthly): 1.28
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 61.92M
Float: 55.03M
Short % of float: 7.01%
Short ratio (days): 10.75
Held by insiders: 2.23%
Held by institutions: 78.27%
Avg volume (3m): 421.19K
50-day average: 1.10
200-day average: 1.19
52-week change: −35.03%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.7
vs 50-day SMA: −11.52%
vs 200-day SMA: −18.45%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.49%
Realised vol (20d, ann.): 41.3%
From 52-week high: −50.36%
From 52-week low: +0.73%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

2.00

+106.61% implied

Low 2.00Median 2.00High 2.00

Recommendation trend

Now0 / 3 / 1
1m ago0 / 4 / 1

Buy / hold / sell counts

DES

About Pliant Therapeutics, Inc.

Yahoo Finance profile

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 49
Headquarters: South San Francisco, CA, United States
Website: pliantrx.com
Officers: Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D. President, CEO & Director
Dr. Keith Lamont Cummings M.B.A., M.D. Chief Financial Officer
Ms. Minnie Kuo Chief Operating Officer
Dr. Rik Derynck Ph.D. Scientific Founder & Member of Scientific Advisory Board

SEAS

Seasonality · PLRX

2020–2026 · monthly returns

Strongest month Jul +19.23%Weakest month Mar −17.27%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.8	7.4	-3.1	-3.2	3.3	-9.5	-8.8	5.8	-1.8	-10.4			−20.7%
2025	-18.4	-68.0	-60.8	17.8	-15.1	-14.1	25.9	12.3	-9.8	13.5	-4.2	-24.2	−90.7%
2024	-1.0	-11.4	-6.1	-20.7	2.6	-11.4	33.1	-7.1	-15.7	25.5	-1.9	-4.6	−27.3%
2023	81.3	-9.1	-16.5	6.2	-23.4	-16.2	-1.5	-5.4	2.7	-15.4	-5.3	30.4	−6.3%
2022	-13.1	-23.5	-21.9	-16.4	-3.9	42.3	116.9	11.0	8.4	19.1	-26.1	5.2	+43.2%
2021	8.3	34.5	18.9	-14.8	-10.3	-3.1	-30.6	-9.7	-7.5	-5.6	-11.0	-4.8	−40.6%
2020							-28.3	8.0	-9.9	-4.5	27.3	-17.4	−30.0%

INSD

Insider Activity · PLRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jan 19, 2026	Coulie Bernard JChief Executive Officer	Sale at price 1.28 per share.	89.4K	$114.40K
Jan 19, 2026	Cummings Keith LamontChief Financial Officer	Sale at price 1.28 per share.	24K	$30.72K
Jan 19, 2026	Cheung LilyOfficer	Sale at price 1.28 per share.	7.5K	$9.64K
Jan 19, 2026	Kuo MinnieChief Operating Officer	Sale at price 1.28 per share.	6.9K	$8.85K
Jan 22, 2025	Lefebvre EricOfficer	Stock Award(Grant) at price 0.00 per share.	45.6K	—
Jan 22, 2025	Hull Johannes P.Officer	Stock Award(Grant) at price 0.00 per share.	40.1K	—
Jan 22, 2025	Coulie Bernard JChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	162.5K	—
Jan 22, 2025	Cummings Keith LamontChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	56.6K	—
Jan 22, 2025	Ouimette MichaelGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	35K	—
Jan 22, 2025	Cheung LilyOfficer	Stock Award(Grant) at price 0.00 per share.	25.9K	—
Jan 21, 2025	Ouimette MichaelGeneral Counsel	Sale at price 10.99 - 11.20 per share.	23.5K	$261.10K
Jan 16, 2025	Lefebvre EricOfficer	Sale at price 11.20 per share.	18.5K	$206.97K
Jan 16, 2025	Hull Johannes P.Officer	Sale at price 11.20 per share.	15.9K	$178.50K
Jan 16, 2025	Coulie Bernard JChief Executive Officer	Sale at price 11.20 per share.	52.4K	$587.15K
Jan 16, 2025	Cummings Keith LamontChief Financial Officer	Sale at price 11.20 per share.	20.1K	$225.68K
Jan 16, 2025	Cheung LilyOfficer	Sale at price 11.20 per share.	3.7K	$41.89K

13F

Investors Holding PLRX

latest 13F filings of 29 followed managers

Investors holding PLRX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.3M	0.00%	2.05M	+11%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PLRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PLRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pliant Therapeutics, Inc.

Seasonality · PLRX

Insider Activity · PLRX

Congress Trades · PLRX

Investors Holding PLRX

Investors Holding PLRX

Congress Trades · PLRX

Insider Activity · PLRX

Seasonality · PLRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pliant Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News